Table 3.

Characteristics of the 23 Hepatitis C Virus Treatment Failures Seen in the Canadian Co-Infection Cohort

Patient	GT	HCV Treatment Experienced	Cirrhosis	HCV Treatment	Prescribed Duration, wk	Actual Duration, wk	Contraindicated Antiretrovirals	Off-Label, Low-Efficacy	Substance Usea	Comorbiditiesb
1	1a	No	No	ELB/GRZ	12	8	None	No	IDU, alcohol	None
2	1a	No	No	SOF/LED	12	8	None	No	IDU	None
3	1a	No	No	SOF/LED	12	11	None	No	None	None
4	1a	No	No	SOF/LED	12	11	None	No	IDU, alcohol	None
5	1a	No	No	SOF/LED	12	12	None	No	None	None
6	1a	No	No	SOF/LED	12	12	None	No	IDU	None
7	1a	No	Yes	SOF+RBV	12	5	None	Yes	None	Kidney disease
8	1a	No	Yes	SOF/LED	8	8	None	Yes	IDU	None
9	1a	No	Yes	SOF/LED	24	24	None	No	None	None
10	1a	Yes	No	SOF/LED	12	12	None	No	None	None
11	1a	Yes	No	SOF/LED	12	12	None	No	IDU	None
12	1a	Yes	Yes	SIM+SOF+RBV	12	6	None	Yes	None	None
13	1a	Yes	Yes	SOF/LED	24	24	None	Yes	None	None
14	1a	Yes	Yes	SOF/LED+RBV	12	12	None	No	Alcohol	None
15	1b	Yes	Yes	SOF/LED	12	7	None	No	None	Diabetes
16	1	No	No	ELB/GRZ	12	12	Darunavir	Yes	None	Kidney disease
17	1	No	No	SOF/LED	12	9	None	No	None	None
18	2	No	No	SOF+RBV	12	10	None	Yes	None	Kidney disease
19	2	No	Yes	SOF+RBV	12	5	None	Yes	None	Diabetes
20	3	No	No	SOF+RBV	24	24	None	Yes	Alcohol	None
21	3	Yes	Yes	SOF+RBV	24	24	None	Yes	Alcohol	Kidney disease
22	4	No	No	SOF/LED	12	12	None	No	None	None
23	4	Yes	Yes	SOF/LED	24	24	None	Yes	None	None

Abbreviations: ELB, elbasvir; GRZ, grazoprevir; GT, genotype; HCV, hepatitis C virus; IDU, injection drug use; LED, ledipasvir; RBV, ribavirin; SIM, simeprevir; SOF, sofosbuvir.

^aHigh-frequency IDU was defined by self-report of injecting crack/cocaine or methamphetamines in the last year before treatment initiation. Hazardous alcohol use was defined by self-report of consumption in the last year before treatment initiation resulting in AUDIT-C scores ≥3 for females or ≥4 for males.

^bDiabetes was defined through clinical diagnosis or 2 consecutive measurements of fasting glucose ≥7 mmol/L or nonfasting glucose ≥11.1 mmol/L before treatment initiation. Kidney disease was defined as a single estimated glomerular filtration rate measurement ≤60 mL/min/1.73 m² before treatment initiation.